Proteome Sciences (LON:PRM) Shares Down 18.5% – Should You Sell?

Shares of Proteome Sciences plc (LON:PRM) traded down 18.5% during trading on Thursday . The stock traded as low as GBX 2.89 ($0.04) and last traded at GBX 2.89 ($0.04). 1,014,536 shares were traded during trading, an increase of 367% from the average session volume of 217,283 shares. The stock had previously closed at GBX 3.55 ($0.05).

Proteome Sciences Stock Performance

The firm has a market cap of £8.54 million, a price-to-earnings ratio of -2.09 and a beta of 0.07. The company has a current ratio of 0.20, a quick ratio of 0.37 and a debt-to-equity ratio of -258.66. The stock’s 50 day moving average is GBX 4.08 and its 200 day moving average is GBX 3.46.

Proteome Sciences (LON:PRM) last posted its earnings results on Thursday, April 10th. The company reported GBX (1.15) (($0.01)) EPS for the quarter. Proteome Sciences had a negative net margin of 0.04% and a negative return on equity of 0.01%.

About Proteome Sciences

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant, provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator, analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids.